Format

Send to

Choose Destination
Br J Dermatol. 2017 Apr;176(4):979-984. doi: 10.1111/bjd.15179. Epub 2017 Mar 2.

Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement.

Author information

1
Department of Dermatology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.
2
Department of Dermatology, Oregon Health & Sciences University, Portland, OR, U.S.A.
3
Medical Sociology, Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany.
4
Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, U.K.
5
Department of Epidemiology and Biostatistics, EMGO+ Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands.
6
Institution for Clinical Science, Department of Dermatology, Lund University, Malmö, Sweden.
7
Department of Rheumatology and Division of Epidemiology, University of Alabama, Birmingham, AL, U.S.A.
8
Veterans Affairs Medical Center, Birmingham, AL, U.S.A.
9
Mayo Clinic College of Medicine, Rochester, MN, U.S.A.
10
Centre for Evidence-based Healthcare, University Hospital Carl Gustav Carus, TU, Dresden, Germany.

Abstract

BACKGROUND:

The Harmonising Outcome Measures for Eczema (HOME) initiative has defined four core outcome domains for a core outcome set (COS) to be measured in all atopic eczema (AE) trials to ensure cross-trial comparison: clinical signs, symptoms, quality of life and long-term control.

OBJECTIVES:

The aim of this paper is to report on the consensus process that was used to select the core instrument to consistently assess symptoms in all future AE trials.

METHODS:

Following the HOME roadmap, two systematic reviews were performed which identified three instruments that had sufficient evidence of validity, reliability and feasibility to be considered for the final COS.

RESULTS:

At the fourth international HOME meeting, there was broad consensus among all stakeholders that the Patient-Oriented Eczema Measure (POEM) should be used as the core instrument (87·5% agreed, 9·4% unsure, 3·1% disagreed).

CONCLUSIONS:

All relevant stakeholders are encouraged to use POEM as the chosen instrument to measure the core domain of symptoms in all future AE clinical trials. Other instruments of interest can be used in addition to POEM.

PMID:
27858989
DOI:
10.1111/bjd.15179
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center